相关实验视频

Updated: Jul 5, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

克拉斯是质母细胞瘤中金反应的分子决定因素

Candida Zuchegna^1,2, Stefano Leone³, Antonella Romano¹

¹Department of Biology, Federico II University of Naples, 80126, Naples, Italy.

|January 15, 2024

概括

克拉斯的表达影响着质母细胞瘤对西斯的反应. MEK 抑制剂通过调节 KRAS 信号和细胞循环停止来增强西斯丁的疗效,这表明 KRAS 是治疗点.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症治疗方法癌症治疗方法

背景情况:

克拉斯是一种关键的瘤基因,尽管在质瘤中突变很罕见.
质母细胞瘤 (GBM) 经常表现出失调的RAS信号传输.
西斯是一种基于的化疗剂,用于治疗各种癌症,包括神经母细胞瘤和脑母细胞瘤.

研究的目的:

调查KRAS表达在质母细胞瘤对西斯丁敏感性的作用.
评估西斯普拉丁和MEK抑制剂对质母细胞瘤细胞的联合作用.

主要方法:

长期的人类质母细胞瘤细胞培养物 (U87MG,U251MG) 用西斯和/或MEK抑制剂PD98059.9进行治疗.
评估了细胞活力 (MTT),蛋白质表达 (Western Blot),细胞周期进展 (PI染色) 和细胞亡 (TUNEL试验).
使用KRAS^G12V等离子体进行了功能增益实验.

主要成果:

西斯普拉丁治疗增加了内源的K-Ras4B蛋白水平,并激活了RAF/MEK/ERK MAPK通路.
MEK 抑制剂 PD98059 增强了西斯普拉丁诱导的细胞毒性和调节的细胞循环停止.
KRAS^G12V的过度表达挽救了西斯胺诱导的亡,而特定的HVR突变逆转了这种效应.

结论:

在基斯普拉丁基的质母细胞瘤化疗中,KRAS充当可操作的标.
对MEK1/2抑制剂与西斯普拉丁结合的临床研究需要进一步研究质母细胞瘤治疗.

关键词:

化学敏感性化学敏感性西斯普拉丁 (Cisplatin) 是一种质母细胞瘤 (glioblastoma) 是一个克拉斯 (Kras) 是一个国家.这是一种MEK抑制剂.

更多相关视频

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Published on: July 31, 2017

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

相关概念视频

The Ras Gene

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...